Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.